Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation.
作者信息
Chen Chao-Long, Ong Aldwin D, Cheng Jen-Yu, Yong Chee-Chien, Lin Chih-Che, Chen Chih-Yi, Cheng Yu-Fan
机构信息
Liver Transplantation Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, China.
Liver Transplantation Center, Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, China.
出版信息
Hepatobiliary Surg Nutr. 2022 Feb;11(1):103-111. doi: 10.21037/hbsn-21-379.
Abstract
摘要
相似文献
1
Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation.质子束治疗将局部晚期肝细胞癌降期或桥接至活体供肝肝移植。
Hepatobiliary Surg Nutr. 2022 Feb;11(1):103-111. doi: 10.21037/hbsn-21-379.
2
Drug-Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation.药物洗脱微球经动脉化疗栓塞术作为活体肝移植前肝细胞癌的桥接治疗
Transplant Proc. 2016 May;48(4):1045-8. doi: 10.1016/j.transproceed.2015.12.078.
3
Long-term outcomes of living donor liver transplantation after locoregional treatment for hepatocellular carcinoma: an experience from a single institute.局部治疗后活体肝移植治疗肝细胞癌的长期结果：单中心经验。
Surg Today. 2021 Mar;51(3):350-357. doi: 10.1007/s00595-020-02095-3. Epub 2020 Aug 7.
4
Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)?肝细胞癌的活体肝移植：是扩大（超出米兰标准）还是降期（至米兰标准）？
Liver Transpl. 2018 Mar;24(3):327-329. doi: 10.1002/lt.25017.
5
Advancements of liver transplantation for hepatocellular carcinoma in Korea.韩国肝细胞癌肝移植的进展
Jpn J Clin Oncol. 2017 Feb 23;47(2):93-100. doi: 10.1093/jjco/hyw168.
6
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.同步放化疗后伴有门静脉肿瘤血栓形成的晚期肝细胞癌的活体肝移植
Yonsei Med J. 2016 Sep;57(5):1276-81. doi: 10.3349/ymj.2016.57.5.1276.
7
Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review.肝癌肝移植的预后因素：文献比较综述。
J Gastrointest Cancer. 2021 Dec;52(4):1223-1231. doi: 10.1007/s12029-021-00730-x. Epub 2021 Dec 9.
8
Liver transplantation: an update 2009.肝移植：2009年最新进展
Curr Opin Gastroenterol. 2009 May;25(3):202-8. doi: 10.1097/MOG.0b013e3283299652.
9
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.ABO 不相容成人活体肝移植治疗肝细胞癌患者的结局。
J Hepatol. 2018 Jun;68(6):1153-1162. doi: 10.1016/j.jhep.2018.02.002. Epub 2018 Feb 13.
10
Surgery for Hepatocellular Carcinoma in Patients with Child-Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation.Child-Pugh B级肝硬化患者肝细胞癌的手术治疗：肝切除术与活体肝移植的比较
World J Surg. 2018 Aug;42(8):2606-2616. doi: 10.1007/s00268-018-4493-1.
引用本文的文献
1
Proton beam therapy for downstaging hepatocellular carcinoma with lobar portal vein tumor thrombosis to living donor liver transplantation.质子束治疗用于将伴有叶门静脉肿瘤血栓形成的肝细胞癌降期以进行活体肝移植
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):966-974. doi: 10.21037/hbsn-23-410. Epub 2023 Nov 15.
2
Proton Beam Therapy for Multifocal Hepatocellular Carcinoma (HCC) Showing Complete Response in Pathological Anatomy After Liver Transplantation.质子束治疗多灶性肝细胞癌（HCC）在肝移植后病理解剖显示完全缓解。
Cureus. 2022 Jun 8;14(6):e25744. doi: 10.7759/cureus.25744. eCollection 2022 Jun.
本文引用的文献
1
The Endless Sources of Hepatocellular Carcinoma Heterogeneity.肝细胞癌异质性的无尽来源
Cancers (Basel). 2021 May 26;13(11):2621. doi: 10.3390/cancers13112621.
2
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.肝癌的联合免疫治疗：放射治疗、免疫检查点阻断及其他。
Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. eCollection 2020.
3
Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter?质子束治疗肝门部肝细胞癌后的胆道并发症要紧吗？
Cancers (Basel). 2020 Aug 24;12(9):2395. doi: 10.3390/cancers12092395.
4
Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis.质子与光子放疗治疗原发性肝细胞癌：倾向评分匹配分析。
Radiat Oncol. 2020 Jun 30;15(1):159. doi: 10.1186/s13014-020-01605-4.
5
Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers.肝细胞癌伴门静脉癌栓患者的治疗：超越已知的边界。
World J Gastroenterol. 2019 Aug 21;25(31):4360-4382. doi: 10.3748/wjg.v25.i31.4360.
6
FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study.FDG-PET 预测活体肝移植受者肿瘤组织学不良；一项回顾性队列研究。
Int J Surg. 2019 Sep;69:124-131. doi: 10.1016/j.ijsu.2019.07.035. Epub 2019 Aug 3.
7
Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.钇-90 经动脉放射性栓塞治疗晚期 HCC：门静脉血栓形成对生存的影响。
PLoS One. 2019 May 29;14(5):e0216935. doi: 10.1371/journal.pone.0216935. eCollection 2019.
8
Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.局部不可切除肝细胞癌的质子束治疗结果。
Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16.
9
Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.质子治疗与光子治疗不可切除肝细胞癌：肝代偿与总生存。
Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):64-72. doi: 10.1016/j.ijrobp.2019.01.076. Epub 2019 Jan 23.
10
What is transplant oncology?什么是移植肿瘤学？
Surgery. 2019 Feb;165(2):281-285. doi: 10.1016/j.surg.2018.10.024. Epub 2018 Nov 22.
Zotero 插件